Pulse Shortwave Therapy in Cervical Osteoarthritis

• Status: Completed
• Trial end date: 2019-07-30
• Target enrollment: 0
• Participant gender: All

Summary

The ActiPatch is an FDA cleared pain therapy device that uses pulsed shortwaves to interrupt pain signals at the nerve. 200 patients will be randomized and divided into an ActiPatch treatment group and comparison analgesic drug therapy group . Subjects will be assessed with the Neck Disability Index (NDI) at baseline and at four weeks and VAS scores will be recorded in order to determine the efficacy of the ActiPatch device compared to Etoricoxib. Cervical osteoarthritis causes chronic neck pain which could potentially be alleviated by the ActiPatch without the use of medication.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: BioElectronics Corporation
• Treatments: Analgesics; Etoricoxib

Criteria

Inclusion Criteria:

• Chronic Neck Pain of > 2 months

• Cervical Osteoarthritis - Radiological Evidence

• Males & females

• Age: 30-60 years

Exclusion Criteria:

• Neck Pain <2 months

• Pregnancy

• Irreversible neck injury

• Congenital Neurological/Muscular Diseases

• Osteo-articular Disorders

• Auto-immune Diseases

• Osteoporosis

• Hematological Diseases (Thalassemia/Sickle Cell Anemia)

• Cancer

• Contra-indication to Etoricoxib 60 mg

• Age <30 or >60 years